GlassScriptPhysician profile
Shamsa A Ali
NPI 1487780755
$35,087.87
in general payments reported to CMS, 2019-2025
52 companies · $2,644 in 2025
The $2,644 reported for 2025 was more than what 81% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $10K · 2021: $1,572 · 2022: $5,531 · 2023: $2,257 · 2024: $1,610 · 2025: $2,644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,421 · Education: $90.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,420.79 |
| Education | $90.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $12,509.96 | 2019-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $7,574.09 | 2019-2021 | |
| Medtronic, INC. | $3,294.74 | 2021-2025 | Accurian, Minimed 780g |
| Novo Nordisk INC | $1,647.38 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,054.88 | 2019-2025 | Ubrelvy, Synthroid |
| Corcept Therapeutics | $886.11 | 2019-2025 | Korlym |
| Lilly USA, LLC | $848.15 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $836.30 | 2019-2025 | |
| Amgen INC. | $797.08 | 2019-2025 | Tepezza, Evenity, Prolia |
| Xeris Pharmaceuticals, INC. | $526.93 | 2021-2025 | Recorlev, Gvoke Hypopen, Keveyis |
| Abbott Laboratories | $493.99 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Bayer Healthcare Pharmaceuticals INC. | $493.01 | 2021-2025 | |
| Amryt Pharma Holdings LTD | $396.56 | 2021-2023 | Mycapssa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $341.32 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amneal Pharmaceuticals LLC | $314.06 | 2019-2025 | Unithroid |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $302.95 | 2019-2025 | Afrezza |
| Antares Pharma, INC. | $286.26 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Dexcom, INC. | $269.44 | 2019-2025 | Dexcom G6 Transmitter |
| Radius Health, INC. | $266.93 | 2019-2024 | Tymlos |
| Ibsa Pharma INC. | $222.99 | 2019-2025 | Tirosint, Licart, Flector |
| Amarin Pharma, INC. | $194.20 | 2020-2022 | |
| Recordati_rare_diseases_inc. | $186.75 | 2022-2025 | Isturisa, Signifor Lar |
| Janssen Pharmaceuticals, INC | $181.78 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $143.87 | 2022-2025 | Strensiq |
| Eusa Pharma (US) LLC | $79.48 | 2022 | |
| Cequr Corporation | $76.66 | 2022-2025 | Cequr Simplicity |
| Pfizer INC. | $74.66 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $67.73 | 2025 | |
| Amphastar Pharmaceuticals, INC. | $64.16 | 2025 | |
| Horizon Therapeutics Plc | $48.49 | 2021-2022 | |
| Tolmar, INC. | $48.17 | 2024-2025 | Jatenzo |
| Tandem Diabetes Care, INC. | $46.44 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Currax Pharmaceuticals LLC | $46.13 | 2023-2025 | Contrave |
| Beta Bionics, INC. | $44.86 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Medtronic Minimed, INC. | $44.12 | 2019-2020 | |
| Ascendis Pharma Endocrinology INC | $43.09 | 2025 | Yorvipath |
| Insulet Corporation | $38.76 | 2025 | Omnipod |
| Acella Pharmaceuticals, LLC | $37.59 | 2025 | NP Thyroid 60 |
| Nevro Corp. | $30.09 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $23.38 | 2025 | Imcivree |
| Madrigal Pharmaceuticals | $22.82 | 2025 | Rezdiffra |
| Ascensia Diabetes Care US INC. | $21.57 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $20.11 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $19.36 | 2022 | |
| Halozyme INC | $18.77 | 2023 | |
| Sequel Med Tech, LLC | $18.69 | 2025 | Twiist |
| Azurity Pharmaceuticals, INC. | $17.24 | 2025 | Azmiro |
| Medline Industries LP | $14.29 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $13.85 | 2023 | Inpefa |
| Alvogen INC | $13.23 | 2023 | Teriparatide |
| Companion Medical, INC. | $12.99 | 2020 | |
| Shire North American Group INC | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shamsa Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.